About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Season's Greetings from Patent Docs | Main | PureCircle USA Inc. v. SweeGen, Inc. (Fed. Cir. 2024) »

December 27, 2023

Comments

On October 03, 2023, Byooviz was also approved as interchangeable.
This Prior Approval supplemental biologics license application proposes BYOOVIZ (ranibizumab-nuna) injection 0.5 mg (10 mg/mL) for intravitreal injection in a single dose
vial to be interchangeable with the corresponding presentation of LUCENTIS (ranibizumab injection) 0.5 mg (10 mg/mL) for intravitreal injection, for the following indications:
• Neovascular (Wet) Age-Related Macular Degeneration (AMD)
• Macular Edema Following Retinal Vein Occlusion (RVO)
• Myopic Choroidal Neovascularization (mCNV)

Thanks - will revise in next iteration.

Good news that approvals are happening so quickly that it is hard to keep up.

Thanks for the information.

The comments to this entry are closed.

June 2024

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30